Company Media Media 2018 Immuron reduces liver inflammation

Immuron reduces liver inflammation

Immuron Limited (ASX: IMC) said results of its IMM-124E phase II Non-Alcoholic Steatohepatitis (NASH) clinical study were positive. Results demonstrate excellent safety and tolerability; statistically significant reduction in serum endotoxin/liposaccharid https://finance.nine.com.au/business-news/immuron-reduces-liver-inflammation/acafdb09-f493-46b9-9d09-1f3af27aba4c

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.

Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies.

The company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.

Payment Options

Contact Information

Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia
Phone: +613 8892 4854
Fax: +613 9899 8533

Filter Categories

Immuron reduces liver inflammation

Partners

Secure Shopping

Get Connected

About Us

Information

Payment Options

Contact Information